A multicentre, retrospective study analysing efficacy of Gemtuzumab Ozogamicin addition to FLAI Induction in Flt3-Itd Mutated Acute Myeloid Leukemia
Latest Information Update: 21 Jul 2020
Price :
$35 *
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Fludarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 21 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association